Cargando…

Specialized Pro-Resolving Lipid Mediators in Cystic Fibrosis

In cystic fibrosis (CF), impaired airway surface hydration (ASL) and mucociliary clearance that promote chronic bacterial colonization, persistent inflammation, and progressive structural damage to the airway wall architecture are typically explained by ion transport abnormalities related to the mut...

Descripción completa

Detalles Bibliográficos
Autores principales: Philippe, Réginald, Urbach, Valerie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6213393/
https://www.ncbi.nlm.nih.gov/pubmed/30241412
http://dx.doi.org/10.3390/ijms19102865
_version_ 1783367756873203712
author Philippe, Réginald
Urbach, Valerie
author_facet Philippe, Réginald
Urbach, Valerie
author_sort Philippe, Réginald
collection PubMed
description In cystic fibrosis (CF), impaired airway surface hydration (ASL) and mucociliary clearance that promote chronic bacterial colonization, persistent inflammation, and progressive structural damage to the airway wall architecture are typically explained by ion transport abnormalities related to the mutation of the gene coding for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) channel. However, the progressive and unrelenting inflammation of the CF airway begins early in life, becomes persistent, and is excessive relative to the bacterial burden. Intrinsic abnormalities of the inflammatory response in cystic fibrosis have been suggested but the mechanisms involved remain poorly understood. This review aims to give an overview of the recent advances in the understanding of the defective resolution of inflammation in CF including the abnormal production of specialized pro-resolving lipid mediators (lipoxin and resolvin) and their impact on the pathogenesis of the CF airway disease.
format Online
Article
Text
id pubmed-6213393
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-62133932018-11-14 Specialized Pro-Resolving Lipid Mediators in Cystic Fibrosis Philippe, Réginald Urbach, Valerie Int J Mol Sci Review In cystic fibrosis (CF), impaired airway surface hydration (ASL) and mucociliary clearance that promote chronic bacterial colonization, persistent inflammation, and progressive structural damage to the airway wall architecture are typically explained by ion transport abnormalities related to the mutation of the gene coding for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) channel. However, the progressive and unrelenting inflammation of the CF airway begins early in life, becomes persistent, and is excessive relative to the bacterial burden. Intrinsic abnormalities of the inflammatory response in cystic fibrosis have been suggested but the mechanisms involved remain poorly understood. This review aims to give an overview of the recent advances in the understanding of the defective resolution of inflammation in CF including the abnormal production of specialized pro-resolving lipid mediators (lipoxin and resolvin) and their impact on the pathogenesis of the CF airway disease. MDPI 2018-09-21 /pmc/articles/PMC6213393/ /pubmed/30241412 http://dx.doi.org/10.3390/ijms19102865 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Philippe, Réginald
Urbach, Valerie
Specialized Pro-Resolving Lipid Mediators in Cystic Fibrosis
title Specialized Pro-Resolving Lipid Mediators in Cystic Fibrosis
title_full Specialized Pro-Resolving Lipid Mediators in Cystic Fibrosis
title_fullStr Specialized Pro-Resolving Lipid Mediators in Cystic Fibrosis
title_full_unstemmed Specialized Pro-Resolving Lipid Mediators in Cystic Fibrosis
title_short Specialized Pro-Resolving Lipid Mediators in Cystic Fibrosis
title_sort specialized pro-resolving lipid mediators in cystic fibrosis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6213393/
https://www.ncbi.nlm.nih.gov/pubmed/30241412
http://dx.doi.org/10.3390/ijms19102865
work_keys_str_mv AT philippereginald specializedproresolvinglipidmediatorsincysticfibrosis
AT urbachvalerie specializedproresolvinglipidmediatorsincysticfibrosis